Enliven Insider Sells $345K Worth of Shares Amid Stock's 62% Yearly Gain
Lori Anne Kunkel, a director at Enliven Therapeutics (NASDAQ:ELVN), sold 10,000 shares worth approximately $345,000 on June 5, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan and marked Kunkel's first open-market transaction of the stock. Enliven’s share price had risen by over 62% in the prior year.
Tickers: $ELVN
Topics: insider trading SEC filing stock ownership